Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
Background: Alpelisib was approved for treatment of breast cancer. We assessed the safety signals associated with alpelisib by data mining the FDA pharmacovigilance database. Methods: Data from the second quarter of 2019 to the fourth quarter of 2022 had been retrieved from the FAERS database. Dispr...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2024-03-01
|
| Серии: | Heliyon |
| Предметы: | |
| Online-ссылка: | http://www.sciencedirect.com/science/article/pii/S2405844024036302 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|